title: The role of angiotensin in obesity and metabolic disease.
abstract: Obesity is associated with increased body fat composition and elevated risk of metabolic and cardiovascular disease. The activity of the renin-angiotensin system is generally increased in obesity and experimental evidence has shown that angiotensin influences appetite and metabolism as well as mechanisms that induce adipose tissue growth and metabolism in peripheral organs. This review summarises some of the key evidence from animal and human experiments that links the renin-angiotensin system to obesity and metabolic disease. This research has been greatly aided by the continuing development of new pharmaceuticals that inhibit the renin-angiotensin system. While their primary use is in the treatment of hypertension and heart failure, a range of experimental and clinical evidence indicates their potential use in the treatment of obesity and metabolic disease.
authors.affiliation: School of Biomedical and Health Sciences, Victoria University, Melbourne, Australia. michael.mathai@vu.edu.au
authors.forename: Michael L
authors.initials: ML
authors.lastname: Mathai
authors.forename: Nora
authors.initials: N
authors.lastname: Chen
authors.forename: Lauren
authors.initials: L
authors.lastname: Cornall
authors.forename: Richard S
authors.initials: RS
authors.lastname: Weisinger
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000809:Angiotensins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D008659:Metabolic Diseases / Q000188:drug therapy / Q000378:metabolism*; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D001786:Blood Glucose